Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Regennera
AddedMar 20, 2024
UpdatedJun 18, 2026
Regennera

Regennera

Regennera: Innovative bone regrowth device with Rutgers IP

HQ
Philadelphia, PA, US
Overview
Compare
Fundraising
Employees

Regennera is developing a novel pre-vascularized, load-bearing synthetic bone graft with IP from Rutgers, The State University of New Jersey.

This all-in-one fracture repair device is capable of developing new bone and vasculature simultaneously by combining a composite polymeric/hydroxyapatite structural element that mimics both trabeculae and cortical bone (which are both critical for proper bone regrowth) and cells from the patient's bone marrow.

Regennera - Similar Companies

Tissue Regeneration Systems logo

Tissue Regeneration Systems

tissuesys.com

Tissue Regeneration logo

Tissue Regeneration

OsteoNovus logo

OsteoNovus

osteonovus.com

RegenX logo

RegenX

Juvent - Regenerative Technologies logo

Juvent - Regenerative Technologies

juvent.com

BioRegenx logo

BioRegenx

bioregenx.com

Renerva logo

Renerva

renerva.com

GeniPhys logo

GeniPhys

geniphys.com

OssiFi logo

OssiFi

ossifi.com

RevOrtho logo

RevOrtho

revortho.com

Vascudyne logo

Vascudyne

Ossio logo

Ossio

ossio.io

Molecular Matrix logo

Molecular Matrix

Eclipse Regenesis logo

Eclipse Regenesis

ReGelTec logo

ReGelTec

regeltec.com

Regennera - Quick Facts

Who are Regennera's competitors?

Companies similar to Regennera include Tissue Regeneration Systems, Tissue Regeneration, OsteoNovus and RegenX.

Where is Regennera's headquarters located?

Regennera's headquarters is located in Philadelphia, PA, US.

When was Regennera's last funding round?

Regennera's most recent funding round was for $50k (USD) in June 2017.

How much has Regennera raised to-date?

As of Jun 13, 2017, Regennera has raised a total of $50k (USD).

How many employees does Regennera have?

Regennera has 5 employees as of Feb 4, 2024.

Regennera - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 4 more industry codes
NAICS
  • 622000Hospitals
  • 622100General Medical and Surgical Hospitals
  • 622110General Medical and Surgical Hospitals
SIC
  • 8060Hospitals